Matsi

The speaker highlights that an analog of Matsi underwent Phase 1A and 1B trials in obese patients with fatty liver. These studies showed statistically significant drops in ALT, AST, and glucose versus placebo, presented at a major liver meeting in 2021.

An FDA advisory committee (PCAC) voted on seven popular peptides in July. Six received a recommendation for inclusion, while one (desipramine mentioned as 'desip' likely referring to a specific compound or error in transcript context of peptides, though desipramine is an antidepressant; the speaker notes it lost due to complex dosing regimen). The speaker emphasizes that this was only a recommendation and not final FDA approval, requiring full formal rulemaking.